We have experienced a successful case of liver metastases from pancreatic ductal adenocarcinoma treated by hepatectomy and adjuvant chemotherapy. A 62-year-old male had undergone pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Thirty days after the surgery, he was given a systemic administration of gemcitabine (GEM) at a dose of 1,000-1,400 mg/body biweekly. Serum CA19-9 was elevated about 8 months after the primary resection. In addition, abdominal CT scan revealed a hepatic metastatic lesion about 10 month after the surgery, We changed the protocol of the chemotherapy to a systemic administration of GEM at a dose of 1,200-1,400 mg/body once a week for 3 weeks with a 1-week rest. Serum CA19-9 was more elevated, so he underwent hepatectomy for liver metastases from pancreatic ductal adenocarcinoma 13 months after the primary surgery, and the adjuvant chemotherapy of GEM restarted at 21 days after the hepatectomy. He has survived without recurrence more than 14 months after the hepatectomy.